About

bioHUBNewCo Team

bioHUB NewCo a Cross-border Data-Driven Lifescience Venture Studio company registered in North America and Asia, created and invested by bioHUB Labs Inc with a focus on licensing and commercialization of "Pre-Clinical and Clinical Stage" Oncology Immuno-Oncology, Metabolic and Rare Diseases Intellectual Property (IP) through a NewCo (a newly formed, independent startup entity).

The Challenge

  1. Legislation: The BIOSECURE Act enacted in December 2025 as part of the FY2026 National Defense Authorization Act, restricts U.S. federal agencies and contractors from using biotechnology equipment or services from designated "foreign adversary" firms.
  2. US Biotech Market: US biotech sector is experiencing a bifurcation, with larger companies facing sharp downgrades due to valuation concerns, and smaller firms struggling with capital constraints resulting in bankruptcy.
  3. Innovation: While the US leads in foundational AI innovation, China dominates in real-world application, "AI-first" drug discovery pipelines, and speed.
Lab Research
The Solution

The Solution

  1. The "NewCo" Model: Instead of direct acquisition, investors are increasingly forming new companies "NewCo") in Western markets to license and develop assets from Chinese Biotech's, offering a more flexible alternative to traditional cross-border M&A.
  2. Cross-border collaboration deepens: China-to-the-West licensing and co-development programs are now a core vector in corporate and business development strategies.
  3. Capital evolution toward alternatives continues: Private equity and structured financing are now mainstream tools.